Study on serum Let-7b in patients with prostate cancer
10.3760/cma.j.issn.1673-4904.2018.09.011
- VernacularTitle:血清Let-7b在前列腺癌患者中的研究
- Author:
Xiaogang GUO
1
;
Tao HAN
;
Pingping HU
;
Changming ZHU
;
Youbao WANG
Author Information
1. 266033,青岛市海慈医疗集团泌尿外科
- Keywords:
Prostatic cancer;
MicroRNAs;
Diagnose;
Prognosis;
Let-7b
- From:
Chinese Journal of Postgraduates of Medicine
2018;41(9):810-813
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the significance of serum Let-7b in prostate cancer (PCa). Methods From July 2015 to September 2016, 72 patients with PCa (PCa group) and 34 healthy people (control group) were selected. The Let- 7b was detected by Western blot and fluorescence quantitative polymerase chain reaction (PCR), and the Let-7b was compared between 2 groups. Results The Let-7b in PCa group was significantly lower than that of control group (0.81 ±0.38 vs.1.31 ±0.34), and there was statistical difference (P<0.01). In PCa group, the Let- 7b in patients with TNM T3 and T4 stage was significantly lower than that in patients with TNM T1 and T2 stage (0.74 ± 0.39 vs. 0.88 ± 0.38), and there was statistical difference (P<0.05); the Let-7b in patients with hormone dependence was significantly higher than that in patients with hormone resistance (1.03 ± 0.40 vs. 0.64 ± 0.27), and there was statistical difference (P<0.05). Receiver operating characteristics curve analysis result showed that Let-7b sensitivity and specificity were 72.2％ and 88.2％ in the diagnosis of PCa. Conclusions Let-7b can indicate the degree of malignancy of the tumor and the hormone resistance. For patients with the high risk of early diagnosis of refractory PCa, the patients′ individualized treatment plan could be adjusted.
